Vaxcyte Inc (PCVX) concluded trading on Thursday at a closing price of $92.68, with 4.3 million shares of worth about $398.84 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 22.84% during that period and on November 14, 2024 the price saw a loss of about -4.09%. Currently the company’s common shares owned by public are about 124.64M shares, out of which, 120.00M shares are available for trading.
Stock saw a price change of -9.76% in past 5 days and over the past one month there was a price change of -21.41%. Year-to-date (YTD), PCVX shares are showing a performance of 47.58% which increased to 87.04% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $48.24 but also hit the highest price of $121.06 during that period. The average intraday trading volume for Vaxcyte Inc shares is 1.02 million. The stock is currently trading -13.34% below its 20-day simple moving average (SMA20), while that difference is down -16.62% for SMA50 and it goes to 11.89% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Vaxcyte Inc (NASDAQ: PCVX) currently have 124.64M outstanding shares and institutions hold larger chunk of about 101.63% of that.
The stock has a current market capitalization of $11.55B and its 3Y-monthly beta is at 0.96. It has posted earnings per share of -$4.68 in the same period. It has Quick Ratio of 17.88 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PCVX, volatility over the week remained 5.35% while standing at 4.46% over the month.
Stock’s fiscal year EPS is expected to rise by 4.99% while it is estimated to decrease by -19.10% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on December 07, 2023 offering a Buy rating for the stock and assigned a target price of $69 to it. On January 03, 2023, Needham Reiterated their recommendations, while on December 15, 2022, Guggenheim Initiated their ratings for the stock with a price target of $66. Stock get a Buy rating from BTIG Research on November 17, 2022.
